Cargando…

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer

High expression of immune checkpoint receptors (ICRs) in the tumor microenvironment regulates the anti-tumor response. In this study, the differential expressions of ICRs on tumor-infiltrating lymphocytes (TILs) in patients with early-stage breast cancer were investigated. The study included 32 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Mollavelioglu, Baran, Cetin Aktas, Esin, Cabioglu, Neslihan, Abbasov, Aykhan, Onder, Semen, Emiroglu, Selman, Tükenmez, Mustafa, Muslumanoglu, Mahmut, Igci, Abdullah, Deniz, Gunnur, Ozmen, Vahit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587596/
https://www.ncbi.nlm.nih.gov/pubmed/36271406
http://dx.doi.org/10.1186/s12957-022-02810-z
_version_ 1784813940060979200
author Mollavelioglu, Baran
Cetin Aktas, Esin
Cabioglu, Neslihan
Abbasov, Aykhan
Onder, Semen
Emiroglu, Selman
Tükenmez, Mustafa
Muslumanoglu, Mahmut
Igci, Abdullah
Deniz, Gunnur
Ozmen, Vahit
author_facet Mollavelioglu, Baran
Cetin Aktas, Esin
Cabioglu, Neslihan
Abbasov, Aykhan
Onder, Semen
Emiroglu, Selman
Tükenmez, Mustafa
Muslumanoglu, Mahmut
Igci, Abdullah
Deniz, Gunnur
Ozmen, Vahit
author_sort Mollavelioglu, Baran
collection PubMed
description High expression of immune checkpoint receptors (ICRs) in the tumor microenvironment regulates the anti-tumor response. In this study, the differential expressions of ICRs on tumor-infiltrating lymphocytes (TILs) in patients with early-stage breast cancer were investigated. The study included 32 patients who underwent surgery with a diagnosis of early-stage breast cancer between September 2018 and March 2020. TIL isolation was performed using a MACS tumor separation device and tumor separation kit. PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT expression of cytotoxic T and natural killer (NK) cells on TILs and peripheral blood lymphocytes (PBLs) were determined by flow cytometry. Patients with a high Ki-67 index, high TIL density, and HER-2 positivity were more likely to have increased CD16(+)CD56(dim) NK cells on TILs. Patients with T2 tumors were more likely to have increased expression of PD-1, LAG-3, and TIGIT on tumor-infiltrating CD8(+) cytotoxic T cells than those with T1 tumors. PD-1, CTLA-4, TIGIT, LAG-3, and TIM-3 expression of CD8(+) T and CD16(-)CD56(bright) NK cells in TILs showed significant positive correlations with each other. PD1(+)CD8(+), TIGIT(+)CD16(+), and CTLA-4(+)CD56(+) cells in PBLs and TILs were found to be negatively correlated, whereas only TIM-3(+) expression of CD8(+) T and CD16(+)CD56(dim) cells in PBLs and TILs showed positive correlations. Our results suggest that CD16(+)CD56(dim) NK cells on TILs may play a major role in the immune response against HER2-positive or highly proliferating breast tumors in patients with early-stage breast cancer. Furthermore, various ICRs were found to be highly co-expressed with each other on TILs, including PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT. These receptors may synergistically suppress the response to the tumor, which may trigger immune escape mechanisms in the early stage of carcinogenesis. However, ICR expressions other than TIM3 on PBLs were not found to accompany their counterparts on TILs.
format Online
Article
Text
id pubmed-9587596
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95875962022-10-23 High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer Mollavelioglu, Baran Cetin Aktas, Esin Cabioglu, Neslihan Abbasov, Aykhan Onder, Semen Emiroglu, Selman Tükenmez, Mustafa Muslumanoglu, Mahmut Igci, Abdullah Deniz, Gunnur Ozmen, Vahit World J Surg Oncol Research High expression of immune checkpoint receptors (ICRs) in the tumor microenvironment regulates the anti-tumor response. In this study, the differential expressions of ICRs on tumor-infiltrating lymphocytes (TILs) in patients with early-stage breast cancer were investigated. The study included 32 patients who underwent surgery with a diagnosis of early-stage breast cancer between September 2018 and March 2020. TIL isolation was performed using a MACS tumor separation device and tumor separation kit. PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT expression of cytotoxic T and natural killer (NK) cells on TILs and peripheral blood lymphocytes (PBLs) were determined by flow cytometry. Patients with a high Ki-67 index, high TIL density, and HER-2 positivity were more likely to have increased CD16(+)CD56(dim) NK cells on TILs. Patients with T2 tumors were more likely to have increased expression of PD-1, LAG-3, and TIGIT on tumor-infiltrating CD8(+) cytotoxic T cells than those with T1 tumors. PD-1, CTLA-4, TIGIT, LAG-3, and TIM-3 expression of CD8(+) T and CD16(-)CD56(bright) NK cells in TILs showed significant positive correlations with each other. PD1(+)CD8(+), TIGIT(+)CD16(+), and CTLA-4(+)CD56(+) cells in PBLs and TILs were found to be negatively correlated, whereas only TIM-3(+) expression of CD8(+) T and CD16(+)CD56(dim) cells in PBLs and TILs showed positive correlations. Our results suggest that CD16(+)CD56(dim) NK cells on TILs may play a major role in the immune response against HER2-positive or highly proliferating breast tumors in patients with early-stage breast cancer. Furthermore, various ICRs were found to be highly co-expressed with each other on TILs, including PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT. These receptors may synergistically suppress the response to the tumor, which may trigger immune escape mechanisms in the early stage of carcinogenesis. However, ICR expressions other than TIM3 on PBLs were not found to accompany their counterparts on TILs. BioMed Central 2022-10-21 /pmc/articles/PMC9587596/ /pubmed/36271406 http://dx.doi.org/10.1186/s12957-022-02810-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Mollavelioglu, Baran
Cetin Aktas, Esin
Cabioglu, Neslihan
Abbasov, Aykhan
Onder, Semen
Emiroglu, Selman
Tükenmez, Mustafa
Muslumanoglu, Mahmut
Igci, Abdullah
Deniz, Gunnur
Ozmen, Vahit
High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
title High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
title_full High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
title_fullStr High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
title_full_unstemmed High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
title_short High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
title_sort high co-expression of immune checkpoint receptors pd-1, ctla-4, lag-3, tim-3, and tigit on tumor-infiltrating lymphocytes in early-stage breast cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587596/
https://www.ncbi.nlm.nih.gov/pubmed/36271406
http://dx.doi.org/10.1186/s12957-022-02810-z
work_keys_str_mv AT mollavelioglubaran highcoexpressionofimmunecheckpointreceptorspd1ctla4lag3tim3andtigitontumorinfiltratinglymphocytesinearlystagebreastcancer
AT cetinaktasesin highcoexpressionofimmunecheckpointreceptorspd1ctla4lag3tim3andtigitontumorinfiltratinglymphocytesinearlystagebreastcancer
AT cabiogluneslihan highcoexpressionofimmunecheckpointreceptorspd1ctla4lag3tim3andtigitontumorinfiltratinglymphocytesinearlystagebreastcancer
AT abbasovaykhan highcoexpressionofimmunecheckpointreceptorspd1ctla4lag3tim3andtigitontumorinfiltratinglymphocytesinearlystagebreastcancer
AT ondersemen highcoexpressionofimmunecheckpointreceptorspd1ctla4lag3tim3andtigitontumorinfiltratinglymphocytesinearlystagebreastcancer
AT emirogluselman highcoexpressionofimmunecheckpointreceptorspd1ctla4lag3tim3andtigitontumorinfiltratinglymphocytesinearlystagebreastcancer
AT tukenmezmustafa highcoexpressionofimmunecheckpointreceptorspd1ctla4lag3tim3andtigitontumorinfiltratinglymphocytesinearlystagebreastcancer
AT muslumanoglumahmut highcoexpressionofimmunecheckpointreceptorspd1ctla4lag3tim3andtigitontumorinfiltratinglymphocytesinearlystagebreastcancer
AT igciabdullah highcoexpressionofimmunecheckpointreceptorspd1ctla4lag3tim3andtigitontumorinfiltratinglymphocytesinearlystagebreastcancer
AT denizgunnur highcoexpressionofimmunecheckpointreceptorspd1ctla4lag3tim3andtigitontumorinfiltratinglymphocytesinearlystagebreastcancer
AT ozmenvahit highcoexpressionofimmunecheckpointreceptorspd1ctla4lag3tim3andtigitontumorinfiltratinglymphocytesinearlystagebreastcancer